U.S. patent 7,463,761 includes claims for the general technique of acquiring two-dimensional digital slide images, and using this two-dimensional image as a map for subsequently acquiring three-dimensional images known as z-stacks. “The ability to create and view z-stacks while a glass slide is still in the scanner is critical for specimens that have multiple focal planes, such as frozen sections for example,” said Ole Eichhorn, Aperio’s chief technical officer.
The ’761 patent also includes claims for the high-performance remote viewing of three-dimensional digital slides across a network, including the Internet. “The ability to create and efficiently view three-dimensional whole slide images makes it possible for Aperio to extend the benefits of digital pathology to the field of cytology, including Pap smears,” said Dirk Soenksen, CEO of Aperio. “The recent expansion of our patent portfolio to encompass TDI-, fluorescence- and 3D-scanning, viewing, and analysis continues to reassure customers that Aperio has the broadest freedom to operate in all niches of digital pathology.”
Aperio’s patent portfolio encompasses all of the elements that comprise a digital pathology system, including digital slide creation, data management, advanced visualization, and image analysis. Aperio holds over 30 issued patents and pending patent applications world-wide and is the digital pathology leader in the global market with an installed base of 500 systems in 28 countries.
About Aperio
Aperio is digitizing pathology. We provide systems and services for digital pathology, which is an environment for the management and interpretation of pathology information that originates with the digitization of a glass slide. Aperio’s award-winning ScanScope® slide scanning systems and Spectrum™ digital pathology information management software improve the efficiency and quality of pathology services for pathologists and other professionals. Applications include education, remote viewing, archival and retrieval, basic research and image analysis. Aperio’s products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications. For clearance updates and more information, please visit www.aperio.com.
Contact:
Aperio
Kevin Whiteley, 760-539-1177
Vice President, Marketing
Email Contact
or
Myla
Wagner Public Relations
Myla Wagner, 925-736-7515
Email Contact